drugset

drugset / Trial / NCT02287779

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

NCT02287779 ↗

Phase 1 Completed 84 enrolled Mirum Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.

Timeline

Start: 2015-01-19
Primary completion: 2015-06-19
Completion: 2015-06-19

Publications

Palmer M, Jennings L, Silberg DG, Bliss C, Martin P. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10. doi: 10.1186/s40360-018-0200-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volixibat	Small molecule	20 mg	Oral
Subject	Volixibat	Small molecule	40 mg	Oral
Subject	Volixibat	Small molecule	80 mg	Oral

Indications